OpGen, Inc. (OPGN)
OTCMKTS · Delayed Price · Currency is USD
9.50
+2.48 (35.33%)
Dec 10, 2025, 3:48 PM EST
OpGen Revenue
OpGen had revenue of $9.00M in the twelve months ending September 30, 2025, up 610.97% year-over-year. In the year 2024, OpGen had annual revenue of $5.20M with 52.01% growth.
Revenue (ttm)
9.00M
Revenue Growth
+610.97%
P/S Ratio
7.86
Revenue / Employee
9.00M
Employees
1
Market Cap
70.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.20M | 1.78M | 52.01% |
| Dec 31, 2023 | 3.42M | 811.03K | 31.11% |
| Dec 31, 2022 | 2.61M | -1.70M | -39.45% |
| Dec 31, 2021 | 4.31M | 91.59K | 2.17% |
| Dec 31, 2020 | 4.21M | 715.83K | 20.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
OpGen News
- 1 year ago - OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - GlobeNewsWire
- 1 year ago - OpGen Announced 1-for-10 Reverse Stock Split - GlobeNewsWire
- 1 year ago - OpGen Provides Update on Business Operations and Strategic Opportunities - GlobeNewsWire
- 1 year ago - OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K - GlobeNewsWire
- 1 year ago - OpGen Announces Acquisition of Preferred Stock by David Lazar - GlobeNewsWire
- 2 years ago - OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 2 years ago - OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds - GlobeNewsWire
- 2 years ago - OpGen, Inc. (OPGN) Q2 2023 Earnings Call Transcript - Seeking Alpha